ISA Pharmaceuticals B.V.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From ISA Pharmaceuticals B.V.
Scrip Asks…What Does 2022 Hold For Biopharma? Part 7: People And Planet
Addressing health care inequities, providing a nurturing environment for employees and learning from the pandemic were among the aims expressed by executives surveyed by Scrip.
Scrip Asks…What Does 2022 Hold For Biopharma? Part 5: Clinical Trials
The COVID-19 pandemic drove huge shifts in clinical trial practice and the transformation is expected to continue even after the global health emergency abates. Industry leaders sharing their predictions around clinical development homed in on decentralized trials, digitization and data tools as key topics for 2022.
Scrip Asks...What Does 2022 Hold For Biopharma? Part 3: Technology And Science
Many industry leaders expect broad progress in the field of RNA technologies following the rapid and successful roll-out of mRNA vaccines against COVID-19 last year. Genetic medicines of various types, emerging platforms for tackling previously “undruggable” targets and the microbiome were among other areas singled out as areas to watch in 2022.
Vaccine Therapies Show Promise In Fight Against Cervical Cancer
The eradication of cervical cancer is on the horizon, stirring further competition between biopharma companies developing novel cancer vaccines.
- Drug Delivery
- Drug Discovery Tools
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.